drugset
drugset / Trial / NCT02116959

Alternating Systemic Chemotherapy and Intra-Arterial Melphalan (IAM) Chemotherapy in Children With Intra-Ocular Retinoblastoma

NCT02116959 ↗

Phase 1 Terminated 6 enrolled University of California, San Francisco
Non-randomizedParallel-groupOpen-labelTreatment

Summary

The purpose of this study is to test the safety of the treatment combination of alternating standard chemotherapy and another (melphalan) chemotherapy at different interval schedules. Researchers want to find out what effects, good and/or bad, the treatment combination has on the patients and their retinoblastoma.

Timeline

Start
2014-07-23
Primary completion
2019-05-25
Completion
2019-05-25

Drugs

EvaluationDrugModalityDoseRoute
Subject Carboplatin Small molecule — —
Subject Etoposide Small molecule — —
Subject Melphalan Small molecule — Other
Subject Vincristine Small molecule — —

Indications

intraocular retinoblastoma